Kamada

Kamada

Biotechnology
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

$511.9M

Market Cap • 9/22/2026

1990

(36 years)

Founded

2013

(13 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Israel

Israel

Country

Valuation

P/B

1,9

P/S

2,7

P/EBITDA

11,9

P/OCF

14,3

P/FCF

19,5

P/E

23,3

BVPS

4,6

EPS

0,4

Market Cap

Market Cap

511,9M

EV

453,6M

EV/Revenue

2,4

EV/EBITDA

10,5

EV/EBIT

16,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Dividend Yield 5Y

0,6%

Payout

0%

Retained Earnings

-18,1M

Profitability

Gross Margin

40,8%

EBITDA Margin

22,5%

EBIT Margin

14,5%

Net Margin

11,6%

D&A/EBITDA

0%

R&D/Revenue

5,2%

Capex/Revenue

4,9%

Capex/D&A

61,7%

Capex/OCF

26,4%

SBC/OCF

5,9%

% PPE

13,6%

% Goodwill

7,9%

ROE

8,4%

ROIC

8,9%

Growth

CAGR Revenue 5Y

10,6%

CAGR Op. Income 5Y

15%

CAGR Net Income 5Y

10,8%

CAGR EPS 5Y

1,7%

CAGR OCF 5Y

20,7%

Leverage

N.D./EBITDA

Debt/Equity

0%

Current Ratio

4,1

Quick Ratio

2,3

Interest Coverage

2678,5%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium